LEADS BIOLABS-B (09887): First Patient Enrolled in Phase II Trial of LBL-024 for Front-Line Gastric or Gastroesophageal Junction Adenocarcinoma

Stock News04-21 16:50

LEADS BIOLABS-B (09887) announced that the first patient has been successfully enrolled in a Phase II clinical study evaluating LBL-024, a PD-L1/4-1BB bispecific antibody, for the treatment of first-line locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma. This open-label, multi-center Phase II clinical study is led by Professor Lin Shen from Peking University Cancer Hospital and is currently being conducted simultaneously at multiple hospitals across the country. The trial aims to assess the efficacy and safety of LBL-024 in patients with first-line locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment